Literature DB >> 2985992

Transfusion-associated acquired immunodeficiency syndrome. Evidence for persistent infection in blood donors.

P M Feorino, H W Jaffe, E Palmer, T A Peterman, D P Francis, V S Kalyanaraman, R A Weinstein, R L Stoneburner, W J Alexander, C Raevsky.   

Abstract

To investigate whether infection with human T-cell lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV) may be persistent in asymptomatic persons and to correlate infection with seropositivity, we performed virologic and serologic studies in 25 of 30 persons who were identified as being at high risk for the acquired immunodeficiency syndrome (AIDS) and who had donated blood to patients who later contracted transfusion-associated AIDS. High-risk donors were those who belonged to a high-risk population, had AIDS or a closely related condition, or had a low ratio of helper to suppressor T lymphocytes. We performed similar studies in 6 of the 24 patients with AIDS who had received donations from this group. HTLV-III/LAV was isolated from 22 of the 25 donors, between 12 and 52 months (mean, 28) after they had donated blood, and from all 6 recipients, between 14 and 37 months (mean, 26) after they had received blood. Of the 22 virus-positive donors, 2 have contracted AIDS, 5 have generalized lymphadenopathy, and 15 (68 per cent) remain asymptomatic. Antibodies to HTLV-III/LAV were detectable by the enzyme-linked immunosorbent assay in serum samples obtained from each person at the time the virus was isolated. We conclude that infection with HTLV-III/LAV may be persistent and asymptomatic for years. This demonstration that viremic patients may be asymptomatic supports the use of serologic screening of donated blood to supplement current procedures for the prevention of transfusion-associated AIDS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985992     DOI: 10.1056/NEJM198505163122005

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  AIDS and hepatitis: a guide for obstetrical anaesthetists.

Authors: 
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

2.  Post-PCR sterilization: development and application to an HIV-1 diagnostic assay.

Authors:  S T Isaacs; J W Tessman; K C Metchette; J E Hearst; G D Cimino
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

3.  Detection of human T-cell lymphotropic virus type III-related antigens and anti-human T-cell lymphotropic virus type III antibodies by anticomplementary immunofluorescence.

Authors:  R S Blumberg; E G Sandstrom; T J Paradis; D N Neumeyer; M G Sarngadharan; K L Hartshorn; R E Byington; M S Hirsch; R T Schooley
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

4.  AIDS virus infection: prognosis and transmission.

Authors: 
Journal:  J R Soc Med       Date:  1986-02       Impact factor: 5.344

Review 5.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

6.  Isolation of HTLV-III/LAV from serum proteins for cancer therapy in the Bahamas.

Authors: 
Journal:  CMAJ       Date:  1986-01-15       Impact factor: 8.262

7.  HTLV-III antibodies in hemodialysis patients--a consequence of blood transfusions?

Authors:  K Schaefer; G Asmus; M Hüfler; D von Herrath
Journal:  Klin Wochenschr       Date:  1986-07-01

Review 8.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

9.  Markers of HTLV-III in patients with end stage renal failure treated by haemodialysis.

Authors:  M Goldman; C Liesnard; J L Vanherweghem; N Dolle; C Toussaint; S Sprecher; J Cogniaux; L Thiry
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-19

10.  Absence of risk of human immunodeficiency virus (HIV) infection in recipients of hepatitis B vaccine.

Authors:  P Amoroso; C Izzo; R Smeraglia; G Lettieri; G Maio; G Flaminio; A Giorgio; P Fico; P Pierri; G Tarro
Journal:  Eur J Epidemiol       Date:  1987-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.